Real-world effectiveness of the CoronaVac vaccine in a retrospective population-based cohort in four Colombian cities (2021-2022).

Autor:	Reina-Bolaños CA; Grupo Epidemiología, Universidad de Antioquia, Medellín, Colombia. Electronic address: Carlos.reina@udea.edu.co., Arbeláez-Montoya MP; Grupo Epidemiología, Universidad de Antioquia, Medellín, Colombia; Grupo de Investigación Clínica - PECET (GIC-PECET), Universidad de Antioquia, Medellín, Colombia., Brango H; Department of Mathematics and Statistics, Universidad del Norte, Barranquilla, Colombia., Ortega D; Grupo de investigación EMAP (Estadística y Matemática Aplicadas), Pontificia Universidad Javeriana Cali, Cali, Colombia., Tovar-Acero C; Grupo de Enfermedades Tropicales y Resistencia Bacteriana, Universidad del Sinú, Montería, Colombia., López-Carvajal L; Grupo de Investigación Clínica - PECET (GIC-PECET), Universidad de Antioquia, Medellín, Colombia., Hincapié-Palacio D; Grupo Epidemiología, Universidad de Antioquia, Medellín, Colombia., Agudelo-Vacca AM; District Secretary of Health, Cali, Colombia., Avila-Rodriguez G; District Secretary of Health, Cali, Colombia., Avilés-Vergara PA; Grupo de Enfermedades Tropicales y Resistencia Bacteriana, Universidad del Sinú, Montería, Colombia., Minotta-Díaz IL; Grupo de investigación COVEP; Grupo de investigación en Economía, Gestión y Salud (ECGESA), Pontificia Universidad Javeriana Cali, Cali, Colombia., Arango-Londoño D; Grupo de investigación EMAP (Estadística y Matemática Aplicadas), Pontificia Universidad Javeriana Cali, Cali, Colombia., Quintero-Mona G; Grupo de investigación COVEP., Sánchez-Orozco M; Grupo de investigación COVEP., Espinoza-Maca LD; Grupo de investigación COVEP., Roa P; District Secretary of Health, Cali, Colombia; Grupo de investigación COVEP., Alzate-Ángel JC; Grupo Epidemiología, Universidad de Antioquia, Medellín, Colombia., Garcés-Hurtado A; District Secretary of Health, Cali, Colombia; Grupo de investigación COVEP., Reina S; Grupo de investigación COVEP., Concha-Eastman A; District Secretary of Health, Cali, Colombia.
Jazyk:	angličtina
Zdroj:	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2024 Oct; Vol. 147, pp. 107156. Date of Electronic Publication: 2024 Aug 02.
DOI:	10.1016/j.ijid.2024.107156
Abstrakt:	Objectives: The National Vaccination Plan against SARS-CoV-2/COVID-19 was launched by the Ministry of Health and Social Protection on 14 February 2021. The main objective of this study was to evaluate the effectiveness of the CoronaVac in preventing the three clinical outcomes of infection, hospitalisation, or death, in a real-world scenario. Design: This was a population-based retrospective dynamic cohort study using a multivariate Cox model to calculate hazard ratios to estimate vaccine effectiveness from 17 February 2021 to 30 June 2022. The data were collected from surveillance systems for 12 months for each individual. Four cities were selected on the basis of the reliability of their data bases. Results: The rates of CoronaVac effectiveness were 32% (95% confidence interval [CI] 31-33) for preventing infection, 55% (95% CI 54-56) for hospitalisation, and 90% (95% CI 89-90) for death, at the end of follow-up. These findings were more consistent during the first 4 months. Compared with the unvaccinated group, homologous booster doses appeared to increase effectiveness in preventing hospitalisation, whereas heterologous booster doses increased protection for both hospitalisation and death. Booster doses did not improve effectiveness among those already vaccinated with CoronaVac, even when they received heterologous boosters. Conclusions: CoronaVac demonstrated effectiveness in preventing death and hospitalisation during the first year of follow-up, but its effectiveness in preventing infection was lower, decreasing rapidly after the first 4 months of follow-up. The effectiveness was higher among children aged between 3 and 12 years, and among adults aged ≥60 years. Booster doses did not improve effectiveness among those already vaccinated with CoronaVac. Competing Interests: Declarations of competing interest The authors have no competing interests to declare. (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu